AMS Menopause Certification Exam 2026–2027 | MSCP Menopause Society
Certified Practitioner Study Guide & Practice Exam | Menopause
Certification Exam Prep | STRAW+10, Menopausal Transition, Hormone
Therapy, MHT, Vasomotor Symptoms, GSM, Nonhormonal Treatments, Bone
Health, Osteoporosis, Cardiovascular Health, Sexual Health, Menopause
Pharmacology, Clinical Management | Practice Questions & Detailed
Rationales
Question 1: According to the STRAW+10 staging system, which criterion defines
the early menopausal transition (Stage -2)?
A. Amenorrhea lasting 60 days or more
B. Persistent difference of 7 days or more in the length of consecutive menstrual
cycles
C. Complete cessation of menstruation for 12 consecutive months
D. Subtle changes in cycle length with less than 7-day variation
CORRECT ANSWER: B. Persistent difference of 7 days or more in the length of
consecutive menstrual cycles
Rationale: The STRAW+10 system defines early menopausal transition (Stage -2)
by increased variability in menstrual cycle length, specifically a persistent
difference of 7 or more days between consecutive cycles. This reflects
intermittent anovulation and fluctuating hormone levels. Late menopausal
transition (Stage -1) requires 60 days or more of amenorrhea, while menopause
itself is defined retrospectively after 12 months of amenorrhea.
Question 2: Which ovarian biomarker is considered the most sensitive and
robust predictor of time to menopause in late reproductive-age women?
A. Follicle-stimulating hormone (FSH)
B. Estradiol
C. Anti-Müllerian hormone (AMH)
D. Inhibin B
CORRECT ANSWER: C. Anti-Müllerian hormone (AMH)
Rationale: AMH, produced by preantral and small antral follicles, reflects the
remaining primordial follicle pool and declines predictably with age. Unlike FSH
and estradiol, which fluctuate dramatically during perimenopause, AMH remains
,relatively stable across the menstrual cycle and is the most robust predictor of
time to menopause. FSH becomes elevated only after significant ovarian reserve
depletion, making it a lagging indicator rather than a predictive marker.
Question 3: A 38-year-old woman presents with 12 months of amenorrhea, hot
flashes, and vaginal dryness. Her FSH is 65 IU/L. What is the most appropriate
diagnosis?
A. Physiologic perimenopause
B. Primary ovarian insufficiency (POI)
C. Late menopausal transition
D. Early postmenopause
CORRECT ANSWER: B. Primary ovarian insufficiency (POI)
Rationale: POI is defined as loss of ovarian function before age 40, characterized
by oligomenorrhea or amenorrhea for at least 4 months with two FSH levels in
the menopausal range (>25 IU/L) drawn at least 4 weeks apart. At age 38 with
elevated FSH and menopausal symptoms, this is POI rather than physiologic
perimenopause. POI requires hormone replacement for bone and cardiovascular
protection until the natural age of menopause.
Question 4: Which endocrine event best explains the occurrence of elevated
estradiol levels during perimenopause, sometimes resulting in "estrogen
dominance" symptoms?
A. Decreased FSH secretion from the pituitary
B. Luteal Out of Phase (LOOP) event with second follicle recruitment
C. Increased inhibin B production
D. Enhanced negative feedback from the ovary
CORRECT ANSWER: B. Luteal Out of Phase (LOOP) event with second follicle
recruitment
Rationale: The LOOP event explains elevated estrogen in perimenopause: as
ovarian reserve declines, elevated FSH levels may recruit a second follicle during
the luteal phase of an ongoing ovulatory cycle, producing unexpectedly high
estradiol levels superimposed on the mid-to-late luteal phase. This can cause
,unpredictable bleeding and paradoxically high estrogen states. FSH increases (not
decreases) in perimenopause, and inhibin B declines rather than increases.
Question 5: A 52-year-old woman has not had a menstrual period for 14
months. According to STRAW+10, which stage classification is most accurate?
A. Late menopausal transition (-1)
B. Early postmenopause (+1a, +1b, +1c)
C. Late postmenopause (+2)
D. Late reproductive stage (-3)
CORRECT ANSWER: B. Early postmenopause (+1a, +1b, +1c)
Rationale: STRAW+10 defines early postmenopause (+1a, +1b, +1c) as the first 2
years after the final menstrual period. At 14 months of amenorrhea, this patient is
in early postmenopause. Late transition (-1) requires 2-11 months of amenorrhea,
and late postmenopause (+2) begins 5-8 years after the final menstrual period.
Question 6: Which statement best describes the change in the hypothalamic-
pituitary-ovarian (HPO) axis during the menopause transition?
A. The pituitary gland becomes more sensitive to estrogen, suppressing FSH
B. The HPO axis may become less sensitive to estrogen, leading to failed LH surges
C. The hypothalamus increases GnRH pulsatility in response to rising progesterone
D. The ovary becomes more sensitive to FSH, leading to multiple ovulations
CORRECT ANSWER: B. The HPO axis may become less sensitive to estrogen,
leading to failed LH surges
Rationale: As women approach menopause, the HPO axis becomes less sensitive
to estrogen, meaning that even with adequate follicular development and
estradiol secretion, the positive feedback mechanism for an LH surge may fail.
This contributes to cycle irregularity and anovulation. The pituitary does not
become more sensitive to estrogen, and the ovary does not become more
sensitive to FSH.
Question 7: A 55-year-old postmenopausal woman has an FSH of 85 IU/L. Which
statement about postmenopausal ovarian function is correct?
, A. The ovaries cease all hormone production completely
B. The postmenopausal ovary continues producing testosterone and
androstenedione
C. The ovaries resume cyclic estrogen production after age 55
D. Ovarian AMH increases significantly after menopause
CORRECT ANSWER: B. The postmenopausal ovary continues producing
testosterone and androstenedione
Rationale: The postmenopausal ovary continues producing androgens
(testosterone and androstenedione) from theca-interstitial cells, which serve as
substrates for peripheral estrogen conversion. Ovaries do not cease all hormone
production, cyclic estrogen does not resume, and AMH declines to undetectable
levels after menopause.
Question 8: Which hormonal change is the primary driver of vasomotor
symptoms during the menopause transition?
A. Declining inhibin B levels leading to increased FSH secretion
B. Fluctuating and declining estradiol levels disrupting hypothalamic
thermoregulation
C. Stable FSH with declining LH levels
D. Elevated AMH indicating diminished ovarian reserve
CORRECT ANSWER: B. Fluctuating and declining estradiol levels disrupting
hypothalamic thermoregulation
Rationale: Vasomotor symptoms result primarily from fluctuating and declining
estradiol levels that disrupt hypothalamic thermoregulation. The narrowing of the
thermoregulatory neutral zone occurs due to reduced estrogen modulation of
kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the arcuate nucleus. While
FSH rises as a compensatory response, it does not directly cause
thermoregulatory instability.
Question 9: In the first year after the final menstrual period, which hormone is
no longer produced by the ovary?
A. Estradiol
B. Progesterone
Certified Practitioner Study Guide & Practice Exam | Menopause
Certification Exam Prep | STRAW+10, Menopausal Transition, Hormone
Therapy, MHT, Vasomotor Symptoms, GSM, Nonhormonal Treatments, Bone
Health, Osteoporosis, Cardiovascular Health, Sexual Health, Menopause
Pharmacology, Clinical Management | Practice Questions & Detailed
Rationales
Question 1: According to the STRAW+10 staging system, which criterion defines
the early menopausal transition (Stage -2)?
A. Amenorrhea lasting 60 days or more
B. Persistent difference of 7 days or more in the length of consecutive menstrual
cycles
C. Complete cessation of menstruation for 12 consecutive months
D. Subtle changes in cycle length with less than 7-day variation
CORRECT ANSWER: B. Persistent difference of 7 days or more in the length of
consecutive menstrual cycles
Rationale: The STRAW+10 system defines early menopausal transition (Stage -2)
by increased variability in menstrual cycle length, specifically a persistent
difference of 7 or more days between consecutive cycles. This reflects
intermittent anovulation and fluctuating hormone levels. Late menopausal
transition (Stage -1) requires 60 days or more of amenorrhea, while menopause
itself is defined retrospectively after 12 months of amenorrhea.
Question 2: Which ovarian biomarker is considered the most sensitive and
robust predictor of time to menopause in late reproductive-age women?
A. Follicle-stimulating hormone (FSH)
B. Estradiol
C. Anti-Müllerian hormone (AMH)
D. Inhibin B
CORRECT ANSWER: C. Anti-Müllerian hormone (AMH)
Rationale: AMH, produced by preantral and small antral follicles, reflects the
remaining primordial follicle pool and declines predictably with age. Unlike FSH
and estradiol, which fluctuate dramatically during perimenopause, AMH remains
,relatively stable across the menstrual cycle and is the most robust predictor of
time to menopause. FSH becomes elevated only after significant ovarian reserve
depletion, making it a lagging indicator rather than a predictive marker.
Question 3: A 38-year-old woman presents with 12 months of amenorrhea, hot
flashes, and vaginal dryness. Her FSH is 65 IU/L. What is the most appropriate
diagnosis?
A. Physiologic perimenopause
B. Primary ovarian insufficiency (POI)
C. Late menopausal transition
D. Early postmenopause
CORRECT ANSWER: B. Primary ovarian insufficiency (POI)
Rationale: POI is defined as loss of ovarian function before age 40, characterized
by oligomenorrhea or amenorrhea for at least 4 months with two FSH levels in
the menopausal range (>25 IU/L) drawn at least 4 weeks apart. At age 38 with
elevated FSH and menopausal symptoms, this is POI rather than physiologic
perimenopause. POI requires hormone replacement for bone and cardiovascular
protection until the natural age of menopause.
Question 4: Which endocrine event best explains the occurrence of elevated
estradiol levels during perimenopause, sometimes resulting in "estrogen
dominance" symptoms?
A. Decreased FSH secretion from the pituitary
B. Luteal Out of Phase (LOOP) event with second follicle recruitment
C. Increased inhibin B production
D. Enhanced negative feedback from the ovary
CORRECT ANSWER: B. Luteal Out of Phase (LOOP) event with second follicle
recruitment
Rationale: The LOOP event explains elevated estrogen in perimenopause: as
ovarian reserve declines, elevated FSH levels may recruit a second follicle during
the luteal phase of an ongoing ovulatory cycle, producing unexpectedly high
estradiol levels superimposed on the mid-to-late luteal phase. This can cause
,unpredictable bleeding and paradoxically high estrogen states. FSH increases (not
decreases) in perimenopause, and inhibin B declines rather than increases.
Question 5: A 52-year-old woman has not had a menstrual period for 14
months. According to STRAW+10, which stage classification is most accurate?
A. Late menopausal transition (-1)
B. Early postmenopause (+1a, +1b, +1c)
C. Late postmenopause (+2)
D. Late reproductive stage (-3)
CORRECT ANSWER: B. Early postmenopause (+1a, +1b, +1c)
Rationale: STRAW+10 defines early postmenopause (+1a, +1b, +1c) as the first 2
years after the final menstrual period. At 14 months of amenorrhea, this patient is
in early postmenopause. Late transition (-1) requires 2-11 months of amenorrhea,
and late postmenopause (+2) begins 5-8 years after the final menstrual period.
Question 6: Which statement best describes the change in the hypothalamic-
pituitary-ovarian (HPO) axis during the menopause transition?
A. The pituitary gland becomes more sensitive to estrogen, suppressing FSH
B. The HPO axis may become less sensitive to estrogen, leading to failed LH surges
C. The hypothalamus increases GnRH pulsatility in response to rising progesterone
D. The ovary becomes more sensitive to FSH, leading to multiple ovulations
CORRECT ANSWER: B. The HPO axis may become less sensitive to estrogen,
leading to failed LH surges
Rationale: As women approach menopause, the HPO axis becomes less sensitive
to estrogen, meaning that even with adequate follicular development and
estradiol secretion, the positive feedback mechanism for an LH surge may fail.
This contributes to cycle irregularity and anovulation. The pituitary does not
become more sensitive to estrogen, and the ovary does not become more
sensitive to FSH.
Question 7: A 55-year-old postmenopausal woman has an FSH of 85 IU/L. Which
statement about postmenopausal ovarian function is correct?
, A. The ovaries cease all hormone production completely
B. The postmenopausal ovary continues producing testosterone and
androstenedione
C. The ovaries resume cyclic estrogen production after age 55
D. Ovarian AMH increases significantly after menopause
CORRECT ANSWER: B. The postmenopausal ovary continues producing
testosterone and androstenedione
Rationale: The postmenopausal ovary continues producing androgens
(testosterone and androstenedione) from theca-interstitial cells, which serve as
substrates for peripheral estrogen conversion. Ovaries do not cease all hormone
production, cyclic estrogen does not resume, and AMH declines to undetectable
levels after menopause.
Question 8: Which hormonal change is the primary driver of vasomotor
symptoms during the menopause transition?
A. Declining inhibin B levels leading to increased FSH secretion
B. Fluctuating and declining estradiol levels disrupting hypothalamic
thermoregulation
C. Stable FSH with declining LH levels
D. Elevated AMH indicating diminished ovarian reserve
CORRECT ANSWER: B. Fluctuating and declining estradiol levels disrupting
hypothalamic thermoregulation
Rationale: Vasomotor symptoms result primarily from fluctuating and declining
estradiol levels that disrupt hypothalamic thermoregulation. The narrowing of the
thermoregulatory neutral zone occurs due to reduced estrogen modulation of
kisspeptin-neurokinin B-dynorphin (KNDy) neurons in the arcuate nucleus. While
FSH rises as a compensatory response, it does not directly cause
thermoregulatory instability.
Question 9: In the first year after the final menstrual period, which hormone is
no longer produced by the ovary?
A. Estradiol
B. Progesterone
